YD Bio Ltd Files 6-K Report
Ticker: YDESW · Form: 6-K · Filed: Sep 30, 2025 · CIK: 2011674
| Field | Detail |
|---|---|
| Company | Yd Bio Ltd (YDESW) |
| Form Type | 6-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, regulatory-filing
TL;DR
YD Bio Ltd (formerly True Velocity) filed a 6-K, reporting for Q2 2025. Standard foreign private issuer update.
AI Summary
YD Bio Limited, formerly True Velocity, Inc./DE, filed a Form 6-K on September 30, 2025, reporting for the period ending June 30, 2025. The company, incorporated in E9 with its principal executive offices in Taipei City, Taiwan, operates in the Medical Laboratories sector. This filing is a report of a foreign private issuer.
Why It Matters
This filing provides an update on YD Bio Ltd's status as a foreign private issuer, which is relevant for investors tracking the company's regulatory disclosures.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational news that would indicate a change in risk.
Key Players & Entities
- YD Bio Limited (company) — Registrant
- True Velocity, Inc./DE (company) — Former Company Name
- 20250630 (date) — Period of Report
- 20250930 (date) — Filing Date
- 001-42810 (other) — SEC File Number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to serve as a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 for the month of September 2025.
What is the reporting period for this filing?
The conformed period of report for this filing is June 30, 2025.
What was YD Bio Limited's former company name?
YD Bio Limited's former company name was True Velocity, Inc./DE.
Where are YD Bio Limited's principal executive offices located?
YD Bio Limited's principal executive offices are located at 12F., No. 3, Xingnan St., Nangang Dist., Taipei City 115001, Taiwan.
Does YD Bio Limited file annual reports under Form 20-F or Form 40-F?
YD Bio Limited files annual reports under cover of Form 20-F, as indicated by the checked box.
Filing Stats: 343 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2025-09-30 16:30:43
Filing Documents
- ea0257439-6k_ydbio.htm (6-K) — 16KB
- ea025743901ex99-1_ydbio.htm (EX-99.1) — 159KB
- ea025743901ex99-2_ydbio.htm (EX-99.2) — 381KB
- ea025743901ex99-3_ydbio.htm (EX-99.3) — 89KB
- ea025743901ex99-4_ydbio.htm (EX-99.4) — 293KB
- ea025743901ex99-5_ydbio.htm (EX-99.5) — 59KB
- ea025743901ex99-6_ydbio.htm (EX-99.6) — 142KB
- ea025743901ex99-7_ydbio.htm (EX-99.7) — 35KB
- 0001213900-25-093988.txt ( ) — 2816KB
- ydesw-20250630.xsd (EX-101.SCH) — 15KB
- ydesw-20250630_cal.xml (EX-101.CAL) — 9KB
- ydesw-20250630_def.xml (EX-101.DEF) — 88KB
- ydesw-20250630_lab.xml (EX-101.LAB) — 129KB
- ydesw-20250630_pre.xml (EX-101.PRE) — 96KB
- ea0257439-6k_ydbio_htm.xml (XML) — 139KB
Management's Discussion and Analysis of Financial Condition and Results of Operations of YD Biopharma Limited
Management's Discussion and Analysis of Financial Condition and Results of Operations of YD Biopharma Limited 99.4 Unaudited Interim Financial Statements of Breeze Holdings Acquisition Corp. 99.5 Management's Discussion and Analysis of Financial Condition and Results of Operations of Breeze Holdings Acquisition Corp. 99.6 Unaudited Pro Forma Condensed Combined and Consolidated Financial Information 99.7 Press Release dated September 30, 2025 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 104 Cover Page Interactive Data File formatted as Inline XBRL and contained in Exhibit 101 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. YD Bio Limited By: /s/ Edmund Hen Name: Edmund Hen Title: Chief Financial Officer Date: September 30, 2025 2